Fig. 5.
![Fig. 5. The relationship between CAFC-survival and donor engraftment. The percentage of donor engraftment is shown as a function of the residual CAFC per hind limb. The treatment groups are divided into effective (2-week protocols with KL; 5-FU + KL [high dose], 5-FU + KL [low dose], 5-FU + KL [low dose] + G-CSF ) and noneffective (saline, 5-FU alone [1-week and 2-week], 5-FU + KL [1-week]) protocols based on engraftment data in Table 1.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/89/7/10.1182_blood.v89.7.2376/6/bl_0003f5.jpeg?Expires=1725180087&Signature=BHWPdW4j06YmtGsLr0icyUlwIokXdjglUFgGdH1mZ-S6UhB8oVb3WVGUfcF4In7gisIl03s2mte-z28Et1z4GfCUbU~a3J6tatulm3yeZyVtlVeFxdIVsE9yMoMitFpxFecXN~OUEnoBAYTjRyLtSs~o9~ydMnVIEZWllxjGW13BkKt0HL1EyQxjezBKhUCrJeYTzFykrPG2i-z8FEgMuLLZ3aejOOgYnmu23pS6XxxY-XkxZqK6bSd3RRSU3ni5Z48EzfIElYAhBCvrSospDogD3FN260w~xN9moZcNwBnx2ydNAOSFi9mul-3YB9ctgKn0tRsAfrf9QRCxyhUr7Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The relationship between CAFC-survival and donor engraftment. The percentage of donor engraftment is shown as a function of the residual CAFC per hind limb. The treatment groups are divided into effective (2-week protocols with KL; 5-FU + KL [high dose], 5-FU + KL [low dose], 5-FU + KL [low dose] + G-CSF ) and noneffective (saline, 5-FU alone [1-week and 2-week], 5-FU + KL [1-week]) protocols based on engraftment data in Table 1.
